Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.13 +1.09 (+2.21%)
Streaming Delayed Price Updated: 11:04 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
News headline image
Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? ↗
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone. 
Via MarketBeat
News headline image
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Novo Nordisk Stock Investors Need to Know This ↗
The company is using litigation to protect sales of its most popular treatments. 
Via The Motley Fool
News headline image
Novo Nordisk Is Down 70%: Is the Price Too Low To Ignore? ↗
Investors shouldn't expect a V-shaped recovery. 
Via The Motley Fool
News headline image
Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On? ↗
Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide. 
Via Benzinga
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Top Pick for Affordable Growth Investors ↗
NOVO-NORDISK A/S (NVO) offers affordable growth with strong revenue, earnings growth, and fair valuation, making it a top pick for balanced investors. 
Via Chartmill
News headline image
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever ↗
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗
Via Stocktwits
News headline image
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Fir
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
News headline image
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
News headline image
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
News headline image
Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk ↗
Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance. 
Via Benzinga
Topics Earnings
News headline image
Why Novo Nordisk Stock Slipped Today ↗
The Danish pharmaceutical company is fighting a competitive war on several fronts. 
Via The Motley Fool
Topics Lawsuit
News headline image
Is It Time to Buy Biotech Stocks? ↗
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
News headline image
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. 
Via Stocktwits
Topics Earnings
News headline image
Law Offices of Howard G. Smith Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme. ↗
The company is struggling with several headwinds as it works to develop its obesity plan. 
Via Investor's Business Daily
News headline image
Why Is Everyone Talking About Novo Nordisk Stock? ↗
Competition is hurting sales of critical products. 
Via The Motley Fool
News headline image
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy ↗
The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk. 
Via Investor's Business Daily
Topics Earnings
News headline image
Shareholders of Novo Nordisk A/S Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Shareholders of Novo Nordisk A/S Should Contact Levi &amp; Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
A Rough Day for "Dividend Knights" ↗
Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.